deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT03180307

OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

Sponsor: On Target Laboratories, LLC

Conditions Ovarian Cancer
Interventions OTL38 laparotomy near infrared camera imaging system
Updated 14 times since 2017 Last updated: Jan 7, 2022 Started: Jan 26, 2018 Primary completion: Apr 16, 2020 Completion: Oct 16, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Ovarian Cancer, this trial is completed. The trial is conducted by On Target Laboratories, LLC and has accumulated 14 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jun 2017 – ~Feb 2018 · 8 months · monthly snapshot~Feb 2018 – ~May 2018 · 3 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshot~Feb 2019 – ~Sep 2019 · 7 months · monthly snapshot~Sep 2019 – ~Feb 2020 · 5 months · monthly snapshot~Feb 2020 – ~Sep 2020 · 7 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Mar 2022 · 5 months · monthly snapshot~Mar 2022 – ~Jul 2024 · 28 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Mar 2022 — Jul 2024 [monthly]

    Completed PHASE3

  5. Oct 2021 — Mar 2022 [monthly]

    Completed PHASE3

▶ Show 9 earlier versions

  1. Jan 2021 — Oct 2021 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  3. Feb 2020 — Sep 2020 [monthly]

    Recruiting PHASE3

  4. Sep 2019 — Feb 2020 [monthly]

    Recruiting PHASE3

  5. Feb 2019 — Sep 2019 [monthly]

    Recruiting PHASE3

  6. Jun 2018 — Feb 2019 [monthly]

    Recruiting PHASE3

  7. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  8. Feb 2018 — May 2018 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  9. Jun 2017 — Feb 2018 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • On Target Laboratories, LLC
  • SynteractHCR
Data source: On Target Laboratories, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Detroit, United States , Duarte, United States , Kettering, United States , Leiden, Netherlands , Orange, United States , Philadelphia, United States , Phoenix, United States , Rochester, United States , St Louis, United States , Tampa, United States and 1 more location